Author:
Long G.V.,Tykodi S.S.,Schneider J.G.,Garbe C.,Gravis G.,Rashford M.,Agrawal S.,Grigoryeva E.,Bello A.,Roy A.,Rollin L.,Zhao X.
Reference19 articles.
1. OPDIVO (nivolumab) [package insert]. Princeton, NJ: Bristol-Myers Squibb; August 2018.
2. OPDIVO (nivolumab) [summary of product characteristics]. Uxbridge, UK: Bristol-Myers Squibb; July 2018.
3. Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy;Agrawal;J Immunother Cancer,2016
4. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer;Topalian;N Engl J Med,2012
5. Model-based population pharmacokinetic analysis of nivolumab in patients with solid tumors;Bajaj;CPT Pharmacometrics Syst Pharmacol,2017
Cited by
152 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献